- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00260806
Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children
HAART Associated Cardiotoxicity in HIV-Infected Children
Study Overview
Status
Conditions
Detailed Description
BACKGROUND:
HIV-infected children are often given HAART to reduce HIV-associated disease. The long-term effects and toxicities associated with this chronic therapy in children are unknown, but severe cardiotoxicity has been suggested in animal models.
DESIGN NARRATIVE:
The P2C2 HIV-infected pediatric cohort received non-HAART regimens in various intensities. Yet, this cohort has exhibited persistent and significant depression of LV contractility compared to uninfected children (after 5 years of follow-up). These same echocardiographic measures have proven to be independently predictive of mortality. Most of the children in the WITS HIV-infected pediatric cohort have been exposed to HAART at varying times and at varying regimen intensities. By assessing LV structure and function, with the same echocardiographic protocol in the WITS cohort as was used previously in the P2C2 cohort, the study will be able to determine the incremental effects of HAART and non-HAART regimens on LV structure and function. The study will also test the hypothesis that HAART exposure results in impaired mitochondrial function that results in cardiomyopathy. This will be assessed by comparing the parameters of LV structure and function that define cardiomyopathy to the frequency of mitochondrial DNA mutations in cells from these same patients. A nested-case-control study design of mitochondrial mutations will be used to assess the relationship between HAART, mitochondrial compromise, and LV structure and function. Treatment intensity for both HAART and non-HAART regimens will be captured through a cumulative score based on an existing 8-point ordinal scale. Intensity will be measured at three points in time: 1) in utero; 2) during the first year of life; and 3) after the first year of life. Analysis of the longitudinal echocardiographic and mitochondrial data will provide valuable information about dose intensity and the comparative impact of HAART versus less aggressive drug regimens. It will also provide information on the impact of therapy during different stages of child development. Similar longitudinal data on viral load and duration of HIV will enable the investigators to control for the effects of HIV infection on cardiovascular toxicity. The findings will help determine the need for cardiovascular follow-up, prevention, and therapeutic trials.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico
- University of Puerto Rico
-
-
-
-
Florida
-
Miami, Florida, United States, 33101
- University of Miami Miller School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois - Chicago
-
-
Maryland
-
Baltimore, Maryland, United States, 21210
- Clinical Trials and Surveys Corp. (C-TASC)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
New York
-
Brooklyn, New York, United States, 11203
- State University of New York (SUNY)
-
New York, New York, United States, 10027
- Columbia University
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Study participants will be children perinatally infected with HIV who were enrolled in the Women and Infants Transmision Study (WITS).
This cohort will be compared to the historical Pediatric Pulmonary and Cardiovacular Complications Study (P2C2 HIV) cohort of perinatally HIV-infected children not exposed to HAART.
Description
Inclusion Criteria:
- HIV-infected children
- Mothers of children understand and are willing to provide informed consent
- Mothers of children are capable of answering in English or with the help of an interpreter
Exclusion Criteria:
- HIV-infected child who is too young (less than 2 years of age) or otherwise unable to undergo an echocardiogram without sedation
- Mothers of children have maternal diabetes or phenylketonuria
- Mothers of children have a recognized Mendelian or chromosomal defect
- Mothers of children are/were actively receiving chemotherapy for cancer during pregnancy
- Mothers of children used lithium carbonate, anticonvulsants, amphetamines, or angiotensin converting enzyme (ACE) inhibitors on a chronic basis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
1
Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
|
2
Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cardiac systolic function
Time Frame: Measured from 2 years of age to 18 years of age
|
Measured from 2 years of age to 18 years of age
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steven E. Lipshultz, MD, University of Miami
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1318
- R01HL078522 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed